美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BridgeBio Oncology Therapeutics, Inc

4.82

-0.0700-1.43%

成交量：37.42萬

成交額：178.20萬

市值：3.86億

市盈率：-2.12

高：4.86

開：4.86

低：4.74

收：4.89

52周最高：14.87

52周最低：4.71

股本：7,998.87萬

流通股本：3,575.24萬

量比：1.09

換手率：1.05%

股息：- -

股息率：- -

每股收益(TTM):-2.2730

每股收益(LYR):-4.3039

淨資產收益率：-81.92%

總資產收益率：-47.10%

市淨率：1.19

市盈率(LYR):-1.12

資料載入中...

總覽公司新聞資訊公告

BridgeBio Oncology Therapeutics：Bbo-11818與Bbo-10203單藥治療數據更新預計於2026年第四季度發布

Bbot發布Bbo-8520新數據，聚焦Kras突變癌症中Bbo-8520組合（2L+ NSCLC）及Bbo-11818與Bbo-10203組合的戰略重點

摩根大通首予BridgeBio Oncology Therapeutics增持評級，目標價27美元

BridgeBio Oncology Therapeutics公布2026年第一季度財報及公司進展

BridgeBio子公司Bbot獲美國FDA快速通道資格 Bbo-11818用於治療晚期KRAS突變胰腺導管腺癌成人患者

BridgeBio Oncology Therapeutics, Inc：更新版一期臨床數據預計將於2026年下半年公布

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BBOT/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":4.82,"timestamp":1789747076774,"preClose":4.89,"halted":0,"volume":374214,"delay":0,"changeRate":-0.01431492842535775,"floatShares":35752400,"shares":79988687,"eps":-2.273,"marketStatus":"交易中","change":-0.07,"latestTime":"09-18 11:58:36 EDT","open":4.86,"high":4.86,"low":4.74,"amount":1781969.085279,"amplitude":0.02454,"askPrice":4.84,"askSize":140,"bidPrice":4.82,"bidSize":29,"shortable":3,"etf":0,"ttmEps":-2.273,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":4.89,"preHourTrading":{"tag":"盘前","latestPrice":4.87,"preClose":4.89,"latestTime":"09:29 EDT","volume":544,"amount":2715.1629696,"timestamp":1789738199999,"change":-0.02,"changeRate":-0.00409,"amplitude":0.06544},"postHourTrading":{"tag":"盘后","latestPrice":5.09,"preClose":4.89,"latestTime":"19:47 EDT","volume":24662,"amount":122665.47,"timestamp":1789688861649,"change":0.2,"changeRate":0.0409,"amplitude":0.042945},"volumeRatio":1.090917},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":35752400,"roa":"-47.10%","roe":"-81.92%","lyrEps":-4.3039,"volumeRatio":1.090917,"shares":79988687,"dividePrice":0,"high":4.86,"amplitude":0.02454,"preClose":4.89,"low":4.74,"week52Low":4.71,"pbRate":"1.19","week52High":14.87,"institutionHeld":0,"latestPrice":4.82,"committee":-0.656805,"eps":-2.273,"divideRate":0,"volume":374214,"delay":0,"ttmEps":-2.273,"open":4.86,"prevYearClose":12.52,"prevWeekClose":4.95,"prevMonthClose":8.8,"prevQuarterClose":7.62,"fiveDayClose":4.95,"twentyDayClose":9.08,"sixtyDayClose":7.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BBOT","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-05-12","symbol":"BBOT","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.53},{"market":"US","date":"2026-03-05","symbol":"BBOT","fiscalQuarterEnding":"2025/12","expectedEps":-0.67,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-12","symbol":"BBOT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.6364,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":11,"updateTime":1783569600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2026-09-17","current":-2.120546,"percent":1,"low":-11.944957,"twenty":-9.557912,"median":-6.945613,"eighty":-4.351189,"high":-2.095553,"avg":-6.933531,"sd":2.596809,"marketCap":381629510},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-17","current":-10.3182,"twenty":-11.192532,"median":-10.372506,"eighty":-9.601414,"marketCap":902842494},{"date":"2025-10-24","current":-9.838494,"twenty":-11.156298,"median":-10.223893,"eighty":-9.601414,"marketCap":860868237},{"date":"2025-10-31","current":-10.861263,"twenty":-11.08659,"median":-10.23674,"eighty":-9.656742,"marketCap":950360520},{"date":"2025-11-07","current":-11.087539,"twenty":-11.118284,"median":-10.345353,"eighty":-9.745662,"marketCap":970159697},{"date":"2025-11-14","current":-11.205203,"twenty":-11.201583,"median":-10.472068,"eighty":-9.804136,"marketCap":980455269},{"date":"2025-11-21","current":-8.47671,"twenty":-11.192532,"median":-10.345353,"eighty":-9.572151,"marketCap":974262207},{"date":"2025-11-28","current":-8.567184,"twenty":-11.17443,"median":-10.251046,"eighty":-9.478901,"marketCap":984660736},{"date":"2025-12-05","current":-8.0313,"twenty":-11.121014,"median":-10.182434,"eighty":-9.298176,"marketCap":923069447},{"date":"2025-12-12","current":-8.936039,"twenty":-11.105583,"median":-10.084778,"eighty":-9.061365,"marketCap":1027054741},{"date":"2025-12-19","current":-8.389716,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"marketCap":964263621},{"date":"2025-12-26","current":-8.490629,"twenty":-11.051335,"median":-9.938056,"eighty":-8.720294,"marketCap":975861981},{"date":"2026-01-02","current":-8.713334,"twenty":-11.00789,"median":-9.919954,"eighty":-8.650698,"marketCap":1001458361},{"date":"2026-01-09","current":-9.256178,"twenty":-10.960825,"median":-9.809862,"eighty":-8.597806,"marketCap":1063849537},{"date":"2026-01-16","current":-8.003462,"twenty":-10.901088,"median":-9.61327,"eighty":-8.567184,"marketCap":919869900},{"date":"2026-01-23","current":-7.829474,"twenty":-10.885701,"median":-9.557912,"eighty":-8.530995,"marketCap":899872728},{"date":"2026-01-30","current":-8.699415,"twenty":-10.880305,"median":-9.521034,"eighty":-8.553265,"marketCap":999858587},{"date":"2026-02-06","current":-7.063925,"twenty":-10.867923,"median":-9.470009,"eighty":-8.485061,"marketCap":811885173},{"date":"2026-02-13","current":-7.947786,"twenty":-10.83411,"median":-9.398729,"eighty":-8.38554,"marketCap":913470805},{"date":"2026-02-20","current":-7.043047,"twenty":-10.812388,"median":-9.272371,"eighty":-8.35979,"marketCap":809485512},{"date":"2026-02-27","current":-7.13352,"twenty":-10.763512,"median":-9.179623,"eighty":-8.144045,"marketCap":819884041},{"date":"2026-03-06","current":-6.882977,"twenty":-10.695084,"median":-9.036987,"eighty":-8.006246,"marketCap":791088114},{"date":"2026-03-13","current":-5.451193,"twenty":-10.678337,"median":-8.936039,"eighty":-7.945698,"marketCap":730699673},{"date":"2026-03-20","current":-5.403428,"twenty":-10.588779,"median":-8.821207,"eighty":-7.854528,"marketCap":724297048},{"date":"2026-03-27","current":-5.510899,"twenty":-10.477499,"median":-8.762051,"eighty":-7.489849,"marketCap":738702956},{"date":"2026-04-02","current":-5.391486,"twenty":-10.453966,"median":-8.733947,"eighty":-7.421645,"marketCap":722696391},{"date":"2026-04-10","current":-5.287,"twenty":-10.379747,"median":-8.713334,"eighty":-7.088979,"marketCap":708690647},{"date":"2026-04-17","current":-5.504928,"twenty":-10.361645,"median":-8.657658,"eighty":-7.020776,"marketCap":737902628},{"date":"2026-04-24","current":-5.355662,"twenty":-10.30763,"median":-8.605462,"eighty":-6.799463,"marketCap":717894422},{"date":"2026-05-01","current":-5.021307,"twenty":-10.25963,"median":-8.567184,"eighty":-5.98855,"marketCap":673076041},{"date":"2026-05-08","current":-4.692922,"twenty":-10.225879,"median":-8.553265,"eighty":-5.587323,"marketCap":629057988},{"date":"2026-05-15","current":-4.419866,"twenty":-10.182434,"median":-8.490629,"eighty":-5.506122,"marketCap":681079323},{"date":"2026-05-22","current":-4.73149,"twenty":-10.167401,"median":-8.47671,"eighty":-5.429101,"marketCap":729099017},{"date":"2026-05-29","current":-4.595521,"twenty":-10.107271,"median":-8.403635,"eighty":-5.355662,"marketCap":708146799},{"date":"2026-06-05","current":-4.278409,"twenty":-10.091924,"median":-8.379277,"eighty":-5.319839,"marketCap":659281465},{"date":"2026-06-12","current":-3.878121,"twenty":-10.077631,"median":-8.309681,"eighty":-5.287,"marketCap":597598995},{"date":"2026-06-18","current":-3.992489,"twenty":-10.053919,"median":-8.201809,"eighty":-5.246997,"marketCap":615222558},{"date":"2026-06-26","current":-3.997687,"twenty":-9.989006,"median":-8.066098,"eighty":-5.177737,"marketCap":616023629},{"date":"2026-07-02","current":-4.054871,"twenty":-9.965147,"median":-8.010422,"eighty":-5.018919,"marketCap":624835411},{"date":"2026-07-10","current":-4.725485,"twenty":-9.946462,"median":-7.965184,"eighty":-4.959212,"marketCap":728173575},{"date":"2026-07-17","current":-4.319998,"twenty":-9.932881,"median":-7.944306,"eighty":-4.729088,"marketCap":665690034},{"date":"2026-07-24","current":-4.533138,"twenty":-9.923745,"median":-7.895589,"eighty":-4.678698,"marketCap":698533946},{"date":"2026-07-31","current":-4.41877,"twenty":-9.900032,"median":-7.829474,"eighty":-4.589283,"marketCap":680910384},{"date":"2026-08-07","current":-4.56433,"twenty":-9.857488,"median":-7.544133,"eighty":-4.574377,"marketCap":703340373},{"date":"2026-08-14","current":-4.060031,"twenty":-9.815588,"median":-7.439739,"eighty":-4.568002,"marketCap":739388569},{"date":"2026-08-21","current":-3.997399,"twenty":-9.757518,"median":-7.182237,"eighty":-4.533138,"marketCap":727982344},{"date":"2026-08-28","current":-4.041423,"twenty":-9.678478,"median":-7.105682,"eighty":-4.446842,"marketCap":735999771},{"date":"2026-09-04","current":-3.918156,"twenty":-9.605366,"median":-7.063925,"eighty":-4.423586,"marketCap":713550976},{"date":"2026-09-11","current":-2.430137,"twenty":-9.58639,"median":-7.015208,"eighty":-4.3855,"marketCap":442561953},{"date":"2026-09-17","current":-2.095553,"twenty":-9.557912,"median":-6.945613,"eighty":-4.351189,"marketCap":381629510}],"updateTime":1789747116080},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1172791094","title":"BridgeBio Oncology Therapeutics：Bbo-11818與Bbo-10203單藥治療數據更新預計於2026年第四季度發布","url":"https://stock-news.laohu8.com/highlight/detail?id=1172791094","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172791094?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:07","pubTimestamp":1788898029,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics今日宣布，其两款在研药物——Bbo-11818与Bbo-10203的单药治疗数据更新，预计将于2026年第四季度对外公布。值得注意的是，单药治疗的疗效与安全性数据，往往是评估药物潜力的基石。此番更新，不仅关乎BridgeBio在肿瘤学领域的战略布局，亦可能对相关治疗领域的竞争格局产生微妙影响。市场对此期待颇高，而数据的最终呈现，无疑将成为2026年末医药板块的焦点事件之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111874945","title":"Bbot發布Bbo-8520新數據，聚焦Kras突變癌症中Bbo-8520組合（2L+ NSCLC）及Bbo-11818與Bbo-10203組合的戰略重點","url":"https://stock-news.laohu8.com/highlight/detail?id=1111874945","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111874945?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:06","pubTimestamp":1788897977,"startTime":"0","endTime":"0","summary":"Bbot正式公布了其Bbo-8520的最新研究数据，同时明确揭示了公司在肿瘤管线布局上的核心战略方向。值得关注的是，这一战略高度聚焦于二线及以后（2L+）非小细胞肺癌领域的Bbo-8520联合疗法，并将目光延伸至KRAS突变相关癌症中，着力推动Bbo-11818与Bbo-10203的组合方案。从管线排序来看，Bbo-8520在NSCLC 2L+场景中的组合策略被置于首要位置，显示出公司对该适应症临床需求缺口的高度重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177819577","title":"摩根大通首予BridgeBio Oncology Therapeutics增持評級，目標價27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177819577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177819577?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 19:38","pubTimestamp":1783510691,"startTime":"0","endTime":"0","summary":"摩根大通发布研究报告，首次将BridgeBio Oncology Therapeutics, Inc纳入覆盖范围，并给予其“增持”评级。该投行为该股设定了27美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197660362","title":"BridgeBio Oncology Therapeutics公布2026年第一季度財報及公司進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1197660362","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197660362?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 06:09","pubTimestamp":1778623778,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc. 发布了其2026年第一季度的财务业绩，并同步更新了公司运营的最新进展。根据报告，公司目前的现金储备预计足以支持其运营持续至2028年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194150244","title":"BridgeBio子公司Bbot獲美國FDA快速通道資格 Bbo-11818用於治療晚期KRAS突變胰腺導管腺癌成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1194150244","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194150244?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 04:08","pubTimestamp":1776715708,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc（简称Bbot）宣布，其针对晚期KRAS突变胰腺导管腺癌成人患者的创新疗法Bbo-11818，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一认定将加速该候选药物的研发和审评进程，为存在迫切未满足医疗需求的患者群体带来新的治疗希望。\n胰腺导管腺癌作为最常见的胰腺癌类型，其KRAS突变亚型长期以来缺乏有效靶向治疗方案。快速通道资格的获得，不仅体现了Bbo-11818在早期研究中展现出的治疗潜力，也意味着该药物在后续临床试验中可获得与FDA更频繁的沟通交流机会，有望更快推进至上市申请阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181220084","title":"BridgeBio Oncology Therapeutics, Inc：更新版一期臨床數據預計將於2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1181220084","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181220084?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 04:08","pubTimestamp":1776715701,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc 近日透露，其备受关注的一期临床试验更新数据预计在2026年下半年揭晓。这一时间表的公布，为关注该公司研发进展的投资者与行业观察者提供了明确预期。\n此次数据更新对于评估相关候选药物的安全性与初步疗效具有关键意义。公司研发管线的最新动态，或将影响其未来的临床开发策略与市场定位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}